In clinical trials with significant noncompliance the standard intention-to-treat analyses sometimes mislead. Rubin's causal model provides an alternative method of analysis that can shed extra light on clinical trial data. Formulating the Rubin Causal Model as a graphical model facilitates model communication and computation.
|
425
|
Bayes factors
– Kass, Raftery
- 1995
|
|
168
|
Model selection and accounting for model uncertainty in graphical models using Occam's window
– Madigan, Raftery
- 1994
|
|
157
|
Sequential updating of conditional probabilities on directed graphical structures
– Spiegelhalter, Lauritzen
- 1990
|
|
119
|
Bayesian graphical models for discrete data
– Madigan, York
- 1995
|
|
75
|
Assessment and propagation of model uncertainty (with discussion
– Draper
- 1995
|
|
73
|
Estimating causal effects of treatments in randomized and nonrandomized studies
– Rubin
- 1974
|
|
63
|
Statistics and causal inference
– Holland
- 1986
|
|
30
|
BUGS: Bayesian inference using Gibbs sampling (Version 0.6) [Computer program
– Spiegelhalter, Thomas, et al.
- 1997
|
|
27
|
On the application of probability theory to agricultural experiments: essay on principles
– Neyman
- 1923
|
|
10
|
Bayesian inference for causal effects in randomized experiments with noncompliance
– Imbens, Rubin
- 1997
|
|
8
|
Correction for Non-compliance in Equivalence Trials
– Robins
- 1998
|
|
8
|
Bayesian inference for causal effects
– Rubin
- 1978
|
|
7
|
On estimating efficacy from clinical trials
– Sommer, Zeger
- 1991
|
|
7
|
Bayesian approaches to randomized trials (with discussion
– Spiegelhalter, Freedman, et al.
- 1994
|
|
4
|
Impact of vitamin A supplementation on childhood mortality
– Sommer, Tarwotjo, et al.
- 1986
|
|
3
|
Intention to treat in clinical trials
– Fisher, Dixon, et al.
- 1990
|
|
3
|
Trials to assess equivalence: the importance of rigorous methods
– Jones, Jarvis, et al.
- 1996
|
|
2
|
Cytomegalovirus infection in patients with AIDS
– Drew
- 1992
|
|
2
|
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS
– Drew, Ives, et al.
- 1995
|
|
2
|
Food and Drug Administration. Guideline for the Format and Content of the Clinical and Statistical
– FDA
- 1988
|
|
2
|
Oral ganciclovir: A new option for patients with CMV retinitis
– Fisher, Barton
- 1996
|
|
2
|
The derivation of a latent threshold instrumental variable model
– Glickman, Normand
- 1995
|
|
2
|
Analysis of clinical trials by treatment actually received: is it really an option? Statistics in Medicine
– Lee, Ellenberg, et al.
- 1991
|
|
2
|
Statistical issues in the regulation of medicines
– Lewis
- 1995
|
|
2
|
Intention to treat - who should use ITT
– Lewis, Machin
- 1993
|
|
2
|
Oral ganciclovir fails to prevent CMV
– McCarthy
- 1995
|
|
2
|
Analysis as-randomized and the problem of non-adherence: an example from the veterans affairs randomized trial of coronary artery bypass surgery
– Peduzzi, Wittes, et al.
- 1993
|
|
2
|
The hope and the hazards of using compliance data in randomized controlled trials
– Pocock, Abdalla
- 1998
|
|
2
|
Formal modes of statistical inference for causal effects
– Rubin
- 1990
|
|
2
|
Intent to treat: The reductio ad absurdum that became gospel. Pharmacoepidemiology and Drug Safety
– Salsburg
- 1994
|
|
2
|
Virtual benchmark instruction: Cooperative learning for undergraduate statistics education
– Schaffner, Madigan, et al.
- 1997
|
|
2
|
Intention-to-treat analysis and the goals of clinical trials
– Sheiner, Rubin
- 1995
|
|
2
|
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS
– Spector, McKinley, et al.
- 1996
|
|
